BioCryst Pharmaceuticals | BCRX - Pre Tax Profit


BioCryst Pharmaceuticals reported $248.02M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
Alnylam Pharmaceuticals USD 161.14M 77.83M Dec/2025
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
Chugai Pharma JPY 169.9B 13.83B Dec/2025
Daiichi Sankyo JPY 106.73B 48.96B Dec/2025
DBV Technologies USD -33.16M 8.6M Sep/2025
Enanta Pharmaceuticals USD -22.71M 95.08M Dec/2024
Gilead Sciences USD 3.64B 1.21B Sep/2025
GlaxoSmithKline GBP 1.23B 1.23B Dec/2025
Glaxosmithkline GBP 2.46B 569M Sep/2025
Incyte USD 389.94M 92.37M Dec/2025
Ionis Pharmaceuticals USD -228M 99M Dec/2025
Karyopharm Therapeutics USD -39.9M 9.01M Dec/2025
Neurocrine Biosciences USD 239.4M 52.4M Dec/2025
Novavax USD 17.9M 220.94M Dec/2025
PTC Therapeutics USD -139.08M 116.01M Dec/2025
Regeneron Pharmaceuticals USD 1.76B 244.6M Sep/2025
Roche Holding CHF 4.79B 3.01B Jun/2025
Sarepta Therapeutics USD -407.67M 213.63M Dec/2025
Ultragenyx Pharmaceutical USD -128M 51.54M Dec/2025
Vertex Pharmaceuticals USD 1.3B 15.8M Sep/2025